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before age 70 in 91 of 172 countries, and it 
is the third or fourth leading cause of death 
in 22 other countries with ≈18 million new 
cases and 9.5 million deaths worldwide.[1,2]
Concerning these cancer-related deaths, 
≈90% are not associated with primary 
tumors, but with secondary ones origi-
nated by a metastatic process,[3] a dynamic, 
systemic, and poorly understood process 
where primary tumor cells travel through 
the blood and lymphatic vessels to healthy 
tissues where these malignant cells are 
implanted to develop a secondary tumor. 
This process and its formation are inher-
ently inefficient, in the sense that only a 
low percentage of cells can complete the 
metastatic process.[4] When successful, 
the cancer usually becomes incurable.[5] 
The cells heavily involved in this pro-
cess are cancer stem cells (CSCs), a class 
of pluripotent cancer cells that behave 
analogously to normal stem cells in their 
ability to differentiate into the spectrum of 
cell types seen in tumors.[6] Recent studies defends that CSCs 
are immortal tumor-initiating cells that can self-renew and 
have pluripotent capacity. Due to these characteristics, CSCs 
are thought to be the basis for tumor initiation, development, 
metastasis, and recurrence.[7] In this way, a cancer cell from the 
primary tumor performs the following steps to produce metas-
tasis: i) locally invades the surrounding tissues; ii) changes 
phenotype and cell–cell and extracellular matrix-cell (ECM-cell) 
For decades, several attempts have been made to obtain a mimetic model for 
the study of metastasis, the reason of most of deaths caused by cancer, in 
order to solve the unknown phenomena surrounding this disease. To better 
understand this cellular dissemination process, more realistic models are 
needed that are capable of faithfully recreating the entire and essential tumor 
microenvironment (TME). Thus, new tools known as tumor-on-a-chip and 
metastasis-on-a-chip have been recently proposed. These tools incorporate 
microfluidic systems and small culture chambers where TME can be faithfully 
modeled thanks to 3D bioprinting. In this work, a literature review has been 
developed about the different phases of metastasis, the remaining unknowns 
and the use of new models to study this disease. The aim is to provide a 
global vision of the current panorama and the great potential that these 
systems have for in vitro translational research on the molecular basis of the 
pathology. In addition, these models will allow progress toward a personal-
ized medicine, generating chips from patient samples that mimic the original 
tumor and the metastatic process to perform a precise pharmacological 
screening by establishing the most appropriate treatment protocol.
The ORCID identification number(s) for the author(s) of this article 
can be found under https://doi.org/10.1002/smll.202006009.
1. Introduction
Non-communicable diseases (NCDs) are currently responsible 
for the majority of deaths worldwide, and cancer is expected to 
be the leading cause of death and the most significant barrier to 
increased life expectancy in all countries of the world in the 21st 
century. The World Health Organization (WHO) estimates for 
2018 that cancer was the leading or second leading cause of death 
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adhesion through the epithelial-mesenchymal transition (EMT), 
process that confers multiple malignant features associated 
with the loss of epithelial properties and the acquisition instead 
of certain mesenchymal characteristics necessary to the meta-
static process;[8] iii) enters in the microvasculature of the blood 
and lymphatic system (intravasation); iv) survives far from its 
tissue in the bloodstream and lymph; v) translocates through 
the blood system to the microvasculature of a distant tissue 
(extravasation); and finally vi) invades the new tissue where it 
will proliferate and form the secondary tumor (colonization).[5,9]
For years, attempts have been made to generate in vitro 
cancer study models without achieving a mimetic model, due 
to the cancer is a very complex and multifactorial disease in 
which the microenvironment plays an essential role. The con-
ventional 2D in vitro models are not capable of modeling the 
3D TME, which is so fundamental for metastatic processes.[10] 
In this sense, and for a better study, rudimentary 3D models 
began to be generated, such as the use of cellular spheroids 
and hydrogels,[11] to later move on to more complex techniques 
such as bioprinting, capable of organizing cells in a spatially 
precise manner.[12] Thus, transendothelial migration assays of 
tumor cells can be performed, using cancer cell spheroids for 
example, which more accurately model cell–cell and cell-ECM 
interactions between tumor cells and the surrounding tissue 
microenvironment, and endothelial cells that act as a bar-
rier.[13] 3D in vitro tumor models present a great advantage over 
animal models which are not optimal for quick studies and 
high throughput scenarios, because of the often-long experi-
mental time courses and the difficulty of scaling study sizes, 
and are not necessarily predictive of outcomes in humans.[8]
To develop 3D tumor models, bioprinting makes possible to 
create a 3D multicellular construction by adding layer by layer 
a cell-laden biomaterial called bioink. These bioinks can be bio-
compatible hydrogels or liquids that solidify through chemical or 
physical procedures, resulting in hydrogels too.[14] Among all the 
possibilities, the use of hydrogels such as alginate, gelatin meth-
acryloyl (GelMA), collagen or Poly(ethylene glycol) diacrylate 
(PEGDA), is the most optimal option to produce multicellular 
constructs.[15] To control the architecture of these microgels with 
great precision, multiple types of bioprinting could be chosen.[16] 
All of them can be used in combination with organ-on-a-chip, 
which have developed and evolved rapidly over the last decade.
These organ-on-a-chip technologies use hydrogels or orga-
noids generated from human cells with functional and dynamic 
microvascular networks, which can recreate highly promising 
human TME as a new resource for cost-effective and high 
throughput analysis of cancer drugs.[17] The platforms on which 
these hydrogels rest are generally made of polydimethylsiloxane 
(PDMS), which is optically transparent and allows simple and 
reproducible observation at cellular and subcellular levels, 
without disturbing the tissue microenvironment. Moreover, 
the pressure and fluid flow conditions on these platforms are 
easily controlled, making it possible to recreate the character-
istics of the human vascularized tissue microenvironment and 
to closely observe cellular behavior under precise conditions.[18]
The present work provides a new vision about the still 
paradigms of metastasis, showing all of them as well as the 
evolution of the development of new study models to solve 
the unresolved biological processes of this complex pathology. 
Special emphasis will be placed on the new tumor-on-a-chip 
models that involve the use of 3D bioprinting along with 
these new technologies. In this way, a new perspective will 
be addressed to understand how future models will be devel-
oped, in combination with the current ones, which will allow 
to finally understand the metastatic processes and to establish 
a precise pharmacological screening with a small sample of the 
original tumor to implement a personalized medicine adapted 
to each patient.
2. Biological Steps Related to Metastatic Process
Over 90% of cancer-related deaths are due to metastasis. Once 
produced, metastasis is generally uncontrollable, and only in 
very early and localized stages the treatment is effective. The 
metastatic process is multifactorial involving genetic, epige-
netic, and microenvironmental factors in both the primary 
tumor and the organs that receive the metastatic cells.[19] In 
addition, in the TME there are a large number of cells that 
are naturally found in tissues such as T cells, macrophages, 
dendritic cells, B cells, fibroblasts, or neutrophils (Figure  1), 
accompanying the tumor cells which in turn present different 
genetic alterations, allowing them to overcome physical limits, 
spread and colonize a distant organ.[20] During this process, the 
primary tumor cells must acquire the ability to migrate and 
establish themselves in distant organs, a process in which there 
is a continuous evolution and phenotype selection of tumor 
cells capable of surviving all phases of the process, culminating 
in a metastatic phenotype.[21] In this way, metastasis is a suc-
cession of these individual steps,[22,23] in which metastatic cells 
are rare clones that appear in a very small proportion in the 
primary tumor. In animal models, 0.01% or less of the cancer 
cells that enter the circulation become metastatic cells.[24] The 
intrinsic genomic instability presents in tumor cells, evident in 
the chromosomal gains, losses, and rearrangements associated 
with cancer, increases the frequency of alterations necessary to 
acquire this metastatic capability. In this way, DNA integrity 
is compromised by aberrant cell cycle progression, telomeric 
crisis, inactivation of DNA repair genes, and alteration of epige-
netic control mechanisms.[22–24]
Besides, it has been determined that interactions with the 
TME assist in the selection of a highly aggressive phenotype, 
with survival capacity and capable of evading the immune 
response.[25] Subsequently, metastasis will be addressed from 
the different biological processes that occur, such as origin, 
EMT process, premetastatic niche formation, or tumor 
colonization.
2.1. Local Invasion and Origin of Cellular Heterogeneity
Local invasion involves the entry of cancer cells of the primary 
tumor into the stroma associated with the surrounding tumor 
and then into the adjacent parenchyma of normal tissue. To 
invade the stroma, tumor cells must first rupture the base-
ment membrane (BM), a specialized ECM that plays a major 
role in organizing epithelial tissues, in part by separating their 
epithelial and stromal compartments.[26] In addition to the 
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structural roles played by the BM, the components of this ECM 
contain a reservoir of growth factor, such as tumor-derived 
colony-stimulating factor 1 (CSF-1) and macrophage-derived 
epidermal growth factor (EGF).[27–29] These factors are secreted 
by tumor-associated macrophages (TAMs) along with cancer-
associated fibroblasts (CAFs),[30] and facilitate tumor cell inva-
sion through a paracrine signaling loop.[31] These cells are also 
the major source of proteases, such as cysteine cathepsins[32,33] 
and metalloproteinases,[30] which are capable of breaking 
down the proteins in the ECM. Specifically, TAMs facilitate 
angiogenesis and the breakdown and remodeling of the ECM, 
as well as promoting tumor cell motility. Recent studies reveal 
that direct communication between macrophages and tumor 
cells leads to the invasion and exit of tumor cells into the 
blood vessels (intravasation).[28] Thus, different tumor-derived 
signals seem to recruit a subset of monocytes that express a 
marker not normally found in this type of cell and which is 
restricted to endothelial cells, tyrosine-protein kinase receptor 
Tie2, and which are responsible for neoangiogenesis. Sig-
nals for this macrophage recruitment include, among others, 
hypoxia, which induces hypoxia-inducible factors transcription 
factors in these cells. The main targets of this transcription 
factors include genes for many angiogenic factors, such as vas-
cular endothelial growth factor (VEGF), whose action improves 
angiogenesis in these avascular areas.[20] On the other hand, 
CAFs, as an abundant and active population of stromal cells 
in EMT, function as the signaling center and the remodeling 
machine to help create a desmoplastic tumor niche.[30] CAFs 
are fibroblasts found in the stroma of human cancers, but they 
differ from normal fibroblasts in their increased production of 
collagen and ECM proteins[34,35] and in their increased secre-
tion of pro-angiogenic factors, such as fibroblast growth factor 
2 (FGF2) and vascular endothelial growth factor A (VEGFA) 
promoting tumor proliferation.[36]
In addition to these cells, the BM also plays a crucial role 
in signal transduction events within the carcinoma through 
pathways initiated by integrin-mediated adhesions of the cel-
lular matrix. There proteins are the main receptors of cell 
adhesion. Through multifaceted functions such as signaling 
molecules, mechanotransducers and key components of the 
cell migration machinery, such proteins are involved in most 
steps of cancer progression, from the development of a pri-
mary tumor to metastasis, so that the alterations they cause are 
reflected in cell polarity, proliferation, invasion, and survival of 
the cells.[37,38]
Therefore, the invasion is a well-determined and well-known 
process, although questions still arise. There are different cell 
lineages that have an intrinsic capacity for migration. Would 
Figure 1. Graphic representation of the metastatic process. The primary tumor produces local invasion through the epithelium of the tumor organ, 
managing to intravasate the blood and lymphatic vessels to initiate the metastatic process. Tumor cells, individually or in groups together with the 
presence of platelets, start their journey through the bloodstream and lymph, where their survival due to different molecular processes, among which 
the continuous activation of Akt stands out. Once the target organ is reached, already prepared thanks to TDSF and the exosomes released primary 
tumor cells forming the premetastatic niche, colonization occurs to trigger another metastatic process.
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this capacity help certain cell lineages in the invasion process, 
as well as in the subsequent metastatic progression after the 
acquisition of the tumor genotype and phenotype? The answer 
to this question could, in part, explain the high aggressive-
ness and high metastatic capacity of certain types of tumors. 
Furthermore, this could be solved by developing more realistic 
models that would allow the faithful recreation of the human 
TME, as it happens with decellularized matrix hydrogels, which 
will be discussed later.
2.2. Physical Translocation and Spread of the Cancer Cells:  
EMT Process
Cancer cells must acquire the ability to migrate and invade 
with the aim to separate from the primary tumor and begin 
the process of metastasis. These skills allow CSCs, to degrade 
and move through the ECM of the surrounding tissue into the 
blood and lymph vessels, pathways to distant secondary sites 
thanks to its higher tumor initiating capacity.[39] A central ques-
tion, not yet addressed, is whether this acquisition of malignant 
traits, which involves physical translocation and spread of the 
cancer cells, occurs as an almost inevitable consequence of 
primary tumor progression or as an accidental and therefore 
arbitrary product of the tumor.[40] A widely accepted, but as yet 
unproven model of primary tumor formation, postulates that 
cancer cells acquire a sequence of genetic and epigenetic altera-
tions, each of which confers one or another phenotypic form 
for each cell type. Thus, only one of these alterations can trigger 
a clonal expansion of the cells that have acquired it, leading to a 
succession of clonal expansions that resemble a pattern of Dar-
winian evolution, essential for cell migration.[9,41]
A key event in promoting tumor cell migration and invasion 
is the EMT.[42] In the last 3 decades, developmental biologists 
have defined the existence of this cellular biological program, 
which plays a critical role in early embryonic morphogenesis.[43] 
This EMT program also plays a fundamental role in tumor 
processes, conferring on epithelial cells, both normal and neo-
plastic, properties that are critical for invasion and metastatic 
spread, considerably increasing mobility, invasiveness and the 
ability to degrade the components of the ECM.[44] EMT is a 
group of cellular biological programs that share common char-
acteristics but differ in certain critical details, depending on the 
site of the tissue, the degree of malignancy and the contextual 
signals experienced by the individual neoplastic cells. These 
complex programs are orchestrated and coordinated by a series 
of master transcription factors that induce EMT (EMT-TFs), 
including Snail, Slug, Twist, and Zeb.[45,46]
Although it is clear that EMT process is involved in meta-
static events in cancer, its involvement in other events may 
also be highly relevant to tumor progression:[43] i) it causes 
resistance to cell death and senescence, through the expres-
sion of Twist Family BHLH Transcription Factor 1 and 2 
(Twist1 and Twist2), which prevent cells from experiencing 
oncogene induced senescence by inhibiting p16/ink4a and 
p21/cip;[47] (ii) it provides resistance to chemotherapy and 
immunotherapy, thanks to the transcription factor Snail, 
which confers resistance to paclitaxel, adriamycin, to radia-
tion by antagonizing p53-mediated apoptosis[48] and dendritic 
cell-based immunotherapy;[49] iii) it promotes immune survival 
and immunosuppression, by inducing immune tolerance and 
phenotypic changes through immunoedition (tumor selec-
tion process where cancer cells overcome immune restric-
tions during the cancer’s dormant period);[50,51] and iv) it pro-
vides stem cell characteristics, which induces the change from 
E-cadherin to N-cadherin, developing less cell adhesion, as well 
as the expression of Snail, vimentin, and metalloproteases,[43] 
which favor cell polarization and remodeling.
As it can be seen, the role of the EMT phenomenon is 
important, since it helps the cell dissemination thanks to sev-
eral complex molecular processes. However, as we have com-
mented before, the intrinsic characteristics of the cells could 
be sufficient for the cell migration, depending on the cell lin-
eage, which would put in doubt the total need of this process. 
Furthermore, the loss of cell adhesion generated by this pro-
cess highly compromises certain theories of cell migration that 
occur during metastasis, as we will see below. Molecular genetic 
studies in models that specifically simulate human TME may 
reveal how this EMT occurs, and how the TME influences in 
the entire metastatic process.
2.3. Circulation of Tumor Cells in Search of a Target Organ
Individual invasive carcinoma cells and invasive cohorts arising 
from primary tumors may invade the blood and lymphatic 
vasculature of adjacent normal tissues, or the neovasculature 
that has been assembled within the tumors themselves by 
the process of angiogenesis. The resulting intravasation pro-
vides access to a pathway for circulating tumor cells (CTCs) to 
travel to distant sites, where they can seed new metastatic colo-
nies.[52] These travelers can move as single cells or as multicel-
lular groups (Figure 1) with platelets,[53] that can persist in the 
circulation to the small-caliber microvessels of distant tissues 
(often with luminal diameters as small as 8 µm). The resulting 
physical entrapment would seem to ensure that the vast 
majority of intravascular CTCs remain in the general circulation 
for only seconds or minutes after their initial entry into the vas-
culature. Although most CTCs can be rapidly eliminated, it has 
recently been reported that even groups of CTCs are capable of 
maneuvering through capillary-sized vessels, making them like 
a single-cell chain held together by adhesive interactions.[8,54]
Animal models suggest that less than 0.01% of CTCs sur-
vive and are capable of forming metastases, and for this reason 
they need molecular mechanisms that allow them to survive 
away from the primary tumor.[55] Activation of protein kinase B 
(AKT) signaling plays an essential role in the survival of meta-
static tumor cells at multiple anatomical sites. In circulation, 
the tropomyosin receptor kinase B (TrkB) (also called NTRK2) 
inhibits tumor cell anoikis, a programmed cell death induced 
by the detachment of cells from the ECM,[56] by activating the 
phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K)-AKT54 
pathways,[57] whereas in the bone marrow, the SRC kinase 
mediates AKT signaling in response to bone-specific factors.[58] 
In pulmonary metastasis, macrophage binding to tumor cells 
via vascular cell adhesion molecule 1 (VCAM1) and integrin 
b4 triggers AKT56 signaling for prosurvival.[59] It should be 
noted that AKT phosphorylation in Ser473 can be detected in 
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BM in lung cancer patients, and in vitro functional analysis 
supports an important role of AKT1 and AKT3 in proliferation 
and survival, thus highlighting the importance of this enzyme 
and suggesting a blocking strategy for future antimetastatic 
treatments.[60]
Therefore, many genes and molecular events are involved 
in cell survival. However, not only the intrinsic processes to 
the tumor cell would play a fundamental role. External factors 
could also contribute to the future of the metastatic cell. What 
influence do the circulation patterns and the areas through 
which the metastatic cell travels have? Not all cells travel 
through the same circulatory pattern or interact with the same 
organs, and perhaps this interaction could determine the sur-
vival of the migrating cells as well as the organ they will sub-
sequently colonize. The development of more realistic models 
that comprise complex and functional vascular networks will 
allow a more in-depth study of tumor cells survival in the 
bloodstream.
2.4. Premetastatic Niche: A Guide to CTCs
A key step in metastasis is the entry of the CTCs into sec-
ondary sites or distant from the primary organ, in which the 
tumor appeared to become disseminated tumor cells for subse-
quent metastasis; however, this step is critically affected by the 
local microenvironment of the target organ, which determines 
whether colonization of the tumor cells can occur. However, 
primary tumors can “prepare” the local microenvironment of 
distant organs for colonization by tumor cells even before their 
arrival (Figure 1).[61] Tumor cells, either at the primary sites or 
in the circulation, may release soluble factors or extracellular 
microvesicles[62–64] to convert the incipient metastatic sites into 
compatible “premetastatic niches” (PMNs).[55,65]
The premetastatic niche can be defined as a supportive and 
receptive tissue microenvironment that undergoes a series of 
molecular and cellular changes to form the fertile “soil” for 
metastasis that is ready for the colonization of tumor cell, the 
“seeds”. Thus, it supports the settlement of the tumor in the 
distant organ and promotes tumor metastasis.[66] The primary 
tumor-derived components, tumor-mobilized bone marrow-
derived cells (BMDC) and the local stromal microenviron-
ment of the host organ are the three main factors crucial to 
the formation of the PMN. Many molecular and cellular com-
ponents have been identified that contribute to the formation 
of the PMN in different tumor models allowing the recruit-
ment of different cell types for the establishment of the TME 
(Tables  1 and  2). These niche-promoting molecular compo-
nents, in addition to being secreted by tumor cells, can also be 
produced by myeloid cells and stromal cells, working together 
with the cellular components to initiate, polarize, and establish 
a PMN in future metastatic organs.[61]
Soluble molecules secreted by the primary tumor play 
critical roles in preparing distant sites for de novo PMN, 
thus promoting metastasis and even determining metastatic 
organotropism. These tumor-derived primary molecular com-
ponents include tumor-derived secreted factors (TDSF), extra-
cellular vesicles (EV), and other molecular components.[61] 
Several TDSF have been shown to promote the formation of 
PMNs by mobilizing and recruiting myeloid cells directly from 
the bone marrow into the premetastatic niche.[62] For example, 
vascular endothelial growth factor (VEGF)-A and placental 
growth factor (PlGF), derived from a primary tumor, mobilize 
and recruit VEGFR1+VLA-4+ BMDCs to rich premetastatic sites 
in the lung (Table  1).[66] TDSF, such as tumor necrosis factor 
α (TNF-α) and transforming growth factor β (TGF-β), together 
with VEGF-A, induce the expression of S100A8 and S100A9 
in the lung to develop PMNs (Table  1).[70] Moreover, hypoxia 
induces the expression of some factors, such as granulocyte col-
ony-stimulating factor (G-CSF), which can initiate and regulate 
pre-metastatic niche formation.[74]
Tumor-derived EVs potentially travel far from their orig-
inal site to act as potential mediators by educating the target 
organ to generate the pre-metastatic niche. Thus, EVs can be 
grouped into three broad categories: exosomes (30–100  nm 
in diameter), microvesicles (100–1000  nm in diameter), and 
a recently identified population of cancer-derived EVs called 
“′large oncosomes′” (1–10  mm in diameter).[75] The first to be 
mentioned, exosomes, are nano-sized vesicles (30–150  nm in 
diameter) that are secreted by most cells. They are enclosed by 
a lipid bilayer and carry various biomolecules, including pro-
teins, glycans, lipids, metabolites, RNA, and DNA (Table 2).[76] 
Exosomes released from cancer cells contain a number of pro-
teins (Table  2) including oncogenic proteins, integrins, and 
signaling molecules; some are shared between different cell 
types, while others are uniquely packaged, reflecting the cell of 
origin.
Exosomes can also contain various RNA types (Table  2). 
Most researches to this effect showed that microRNAs 
(miRNAs) and non-coding RNAs were the predominant RNA 
species transported by exosomes; however, messenger RNA 
(mRNA), ribosomal RNA (rRNA), and transfer RNA (tRNA) 
were also reported.[80] Exosomal RNA-mediated communica-
tion greatly influences the education of all cells that conforms 
the TME, not only in the target organs of metastasis, but also 
in the primary tumor, playing a key role and, therefore, pre-
senting a high potential as biomarkers of cancer.[85,86] Even 
CSCs can secrete these exosomes; however, it is not yet well 
known but it has been seen how this exosomal release is able 
to induce the EMT process in adjacent cells[87] or even induce 
immunosuppression.[88]
With all this, it could be thought that different types of 
tumors have a metastatic predisposition for another specific 
type of organ. The characteristics of organotropism may be 
innately related to the PMN since certain types of cancer have a 
predisposition to metastasize to specific organs with a selective 
microenvironment. The primary tumor prepares organ-specific 
sites for metastasis by secreting TDSF to change adhesion 
molecules and ECM components in these secondary organs.[61]
Due to the great complexity of this sequential multistep 
process, new questions are constantly emerging. Previously, 
the possible influence of circulation patterns on the survival 
of metastatic cells has been discussed. With this, it would also 
be logical to think that these patterns could influence both the 
formation of the premetastatic niche and future extravasation. 
Future studies and the development of models simulating the 
connection between organs will bring to light the behaviors that 
surely contribute to the metastatic process.
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2.5. Colonization and Adaptation of CTCs in the Target Organ
For CTCs to be successful in colonizing a new target organ, 
an extravasation process is necessary, where the reversal of the 
EMT process plays a very important role. In this way, the mes-
enchymal-epithelial transition (MET) process occurs acquiring 
tumor cells again an epithelial phenotype, which is a more ses-
sile and proliferative phenotype.[89]
In addition, some cancers have a characteristic tendency to 
metastasize to certain organs.[90–92] For example, breast cancer 
extends to the bones, lungs, brain, and liver or distant metastases 
of prostate cancer occur more prominently in bone (Table  3). 
According to Paget’s hypothesis of “seed” versus “soil”, compat-
ibilities between the cancer cells (the seed) and certain distant 
sites (the soil) have been perceived to influence our view of the 
metastatic process for a long time.[24] However, although it is 
well known that there are preferences on the part of the primary 
tumor toward the target organs, much remains to be known 
about these associations. This complexity could be judged, per-
haps simplistically, by a list of the most common tumors and 
their known metastatic tropisms.[83] However, these and other pri-
mary tumors can also form metastases at alternative tissue sites. 
In each case, the tissue microenvironment of a primary tumor 
is likely to differ markedly from the secondary site of spread, 
requiring significant adaptive movements by the newly arrived 
cancer cells. The details of these adaptive programs would appear 
to be dictated by the microenvironment of the starting point (the 
primary tumor) and the microenvironment of the landing site 
(the parenchymal tissue on which a metastasis is found).[7]
The genomic profile of metastasis has been successfully 
used to predict the sites of origin of primary tumors. These 
patterns of gene expression suggest that cancer cells within 
primary tumors acquire patterns that allow their subsequent 
colonization in preference to specific organs. These findings 
Table 1. Molecular and cellular components promoting pre-metastatic niche formation.
Source Molecule Niche-promoting cells/cell target Mechanisms Primary tumor Target Refs.
Tumor-derived VEGF and PlGF VEGFR1+ HPCs Recruits VEGFR1+ BMDCs Lewis lung carcinoma 
and melanoma
Lung [66]
TIMP-1 Neutrophils Drives cancer cell homing to the liver Colon cancer and breast 
carcinoma
Liver [67]
CXCR4 SDF1-expressing cells Recruitment of SDF1-expressing cells Breast cancer Lymph nodes, bone 
marrow, lung and liver
[68]
FN DPP4-expressing endothelial cells Recruitment of DPP4-expressing endo-
thelial cells
Breast cancer Lung [69]
TGF-β CD11b+/Mac1+ myeloid cells; 
CD11b+/Gr-1+
myeloid cells
S100A8/S100A9, SAA3 expression to 
develop an inflammatory PMN; remodels 
lung parenchyma for PMN formation
Lewis lung carcinoma 
and melanoma
Lung [70]





Recruits macrophages and induces 
inflammatory, angiogenic response of 
endothelial cells





Silences PTEN increasing CCL2 to recruit 
myeloid cells into the PMN





Mobilizes MDSCs niche and promotes
metastatic cancer cell seeding





TNF-α CD11b+/Mac1+ myeloid cells Induces lung expression of S100A8/
S100A9, SAA3 and remodels lung paren-
chyma for PMN formation
Lewis lung carcinoma 
and melanoma
Lung [70]
BMDC-derived Id3 VEGFR1+ HPCs Facilitates the mobilization of VEGFR1+ 
cells to the PMN
Lewis lung carcinoma 
and melanoma
Lung [66]
VLA-4 VEGFR1+ HPCs Allows adhesion of the BMDCs in the pre-
metastatic to provide a permissive PMN
Lewis lung carcinoma 
and melanoma
Lung [66]
VEGF, vascular endothelial growth factor; VEGFR-1, vascular endothelial growth factor receptor 1; HPC, hematopoietic progenitor cell; PIGF, placental growth factor; 
TIMP-1, TIMP metallopeptidase inhibitor 1; CXCR-4, C-X-C chemokine receptor type 4; SDF-1, stromal cell-derived factor 1; FN, fibronectin; DPP4, dipeptidyl peptidase 
4 (DPP4); TGF-β, transforming growth factor; CD11b, cluster of differentiation 11b; Mac1, macrophage-1 antigen; Gr1, granulocyte receptor 1; S100A8/S100A9, S100 calcium-
binding protein A8/A9; SAA3, serum amyloid A 3; CD15, cluster of differentiation 15; ANG-2, angiopoietin-2; CCR2, C-C chemokine receptor type 2; Tie-2, tyrosine-protein 
kinase receptor for angiopoietins 2; miR-19a, microribonucleic acid 19a; IBA1, ionized calcium-binding adapter molecule 1; PTEN, phosphatidylinositol 3,4,5-trisphosphate 
3-phosphatase; CCL2, C-C motif chemokine ligand 2; G-CSF, granulocyte colony-stimulating factor;Ly6G, lymphocyte antigen 6 complex locus G6D; Ly6C, lymphocyte 
antigen 6 complex locus C6D; TNF-α, tumor necrosis factor α; Id3, DNA-binding protein inhibitor; VLA-4, very late antigen-4.
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are supported by recent studies showing that genetically dis-
tinct cells subpopulations present in primary tumors are 
responsible for the metastasis. The result of successful coloni-
zation is a rapid expansion of metastasis that can now serve as a 
new focus for the spread of new secondary metastasis showers 
(Figure 1). It is important for the tumor that many of the cancer 
cells that are dispatched from this newly successful metastasis 
can be reversed with a functional colonization program that 
allows them to colonize a limited subset of sites throughout the 
body or multiple different tissue types. Finally, the multitude 
of secondary metastases derived from the first one soon over-
shadow the initiating metastasis that generated them.[99]
To complete the metastatic process, extravasation has to 
occur correctly. This event is similar to the invasion that ini-
tially occurs, although it is not known exactly if the same genes 
are involved. It would even be important to know if those 
different tumors that are predisposed to colonize the same 
organ use the same genes. Furthermore, during the process 
of infiltration and colonization, there is a latency period. What 
happens during this period? How do the cells survive until they 
manage to colonize the target organ? All this could be solved, 
again, with models that represent complex vascular networks 
and, especially in this case, with the synthesis of more sophisti-
cated organoids that allow the deep study of extravasation.
3. Do We Know Everything about Metastasis?
Nowadays, a great number of basic and deep concepts about 
metastasis are known and allow us to develop new techniques to 
fight it. However, there are still many questions to be solved: do 
cells migrate individually or collectively? Currently, it is believed 
that it can happen both ways; if they migrate collectively, how 
do they do it if they have lost most of the cell–cell interactions 
to escape from the primary tumor thanks to the EMT program? 
So how necessary is this EMT process, and is it really essential 
for cell spread? Although EMT is widely accepted as an impor-
tant mode of dissemination of cancer cells, its precise role in the 
behavior of the primary tumor and its essentiality remains unre-
solved. For example, the invasion of primary tumor cells usu-
ally involves the collective migration of large cohorts of cells into 
adjacent tissues rather than the spread of individual carcinoma 
cells, although both models are under debate and it is even 
believed that they could occur at the same time.[55] The organiza-
tion of these cohorts seems to conflict with the behavior of cells 
that have passed through an EMT and have lost the cohesive 
cell–cell interactions. Therefore, these cohorts raise the ques-
tion of whether EMT programs are essential for the eventual 
dissemination of carcinoma cells, as explained above, or instead 
represent only one of several alternative biological cell programs 
that allow dissemination to occur.[55,100]
Also, another question is whether the TME plays a fun-
damental role in tumor development. According to different 
studies, the answer would seem to be a resounding no.[25,36,40] 
Yet, would it be possible to fully develop the tumor without the 
participation of this microenvironment? Why does the TME 
seem to help the tumor when it should protect the individual 
and slow down the growth of the tumor? We should not forget 
that only 0.01% of the cells that manage to escape from the 
tumor to colonize another organ could survive in the blood-
stream. How is such an inefficient process able to be so efficient 
that it accounts for 90% of cancer deaths? How is the commu-
nication between the primary tumor and the rest of the organs? 
Table 2. Exosome cargo and its role in cell–cell communication.
Macromolecule Molecule Cell of origin Mechanisms Refs.
Protein EGFR Gastric cancer Increased localization and proliferation of metastatic cells [77]
Podocalyxin Non-small cell
lung cancer
Modulated integrin trafficking in fibroblasts, increased tumor cell 
migration and invasion
[78]
cMET Melanoma Promoted a pro-metastatic phenotype and mobilization
of BMDCs to PMNs
[62]
MIF Pancreatic cancer Promoted a pro-metastatic phenotype and mobilization
of CTC to liver
[79]
Integrins α6β4, α6β1, αvβ5 Breast cancer Determined organotropism of metastasis [80]
RNA miR-939 Breast cancer Downregulated VE-cadherin, increased HUVEC permeability [81]
miR-221 Cervical squamous cell carcinoma Promoted migration and lymphangiogenesis [82]
miR-105 Breast cancer Promoted a pro-metastatic phenotype and mobilization
of CTC to brain
[82]
MMP1 mRNA Ovarian cancer Interaction with peritoneal mesothelium barrier, promoted metastasis [84]
EGFR, epidermal growth factor receptor; cMet, hepatocyte growth factor receptor; MIF, macrophage migration inhibitory factor; VE-cadherin, vascular endothelial 
cadherin; HUVEC, human umbilical vein endothelial cell; MMP1 mRNA, matrix metalloproteinase-1 mRNA.
Table 3. Incidence of metastasis in different organs after the autopsy (%).
Cancer organ Lung Bone Brain Liver Refs.
Lung – 34 39 21 [93]
Breast 71 71 22 62 [94]
Prostate 45.7 90.1 1.6 25 [95]
Melanoma 71.3 48.6 54.6 58.3 [96]
Liver 44 8 1 – [97]
Colon 32 8 5 70 [98]
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There are a large number of molecules that serve as a commu-
nication pathway between both,[86,101] and even CSCs are capable 
of releasing exosomes, but do they play a more important role 
in this regard? Why does the above-mentioned organotropism 
exist? And, in another sense, why is there so much heteroge-
neity in the patterns between individuals? Different studies have 
revealed that the degree of intratumoral heterogeneity (ITH) in 
the same patient can be very variable, from 0 to more than 8000 
coding mutations that are heterogeneous within primary tumors 
or between primary and metastatic or recurrence sites.[102] Will 
we be able to find any kind of pattern among patients despite 
this very high intratumoral variability?
The answer to all these questions will be the key to get this 
percentage of dead people to decrease, obtaining an effective 
treatment for this falsely inefficient process with new models, 
which will help us to understand it. Thus, there are different 
study models (models in mice, 3D bioprinting models or lab-
on-chip researches) that have helped to understand all the 
processes that have been previously discussed and that have 
logically served to fight against this disease. However, in order 
to discover all the pieces of this biological puzzle and unravel 
the controversies that exist around it, it is necessary to move 
toward new and more accurate research models. The approach 
to reality with new models will surely allow answering all 
these questions, faithfully imitating the TME and, therefore, 
obtaining more positive, truthful, and objective results.
4. Study Models for Metastasis Research
2D in vitro tumor models have made possible to understand 
the genetic and epigenetic alterations that can initiate or con-
tribute to the proliferation of cancer cells and other tumor 
pheno types.[103] However, as discussed throughout this review, 
the impact of the TME is significantly important[104] and it is 
not present in 2D conventional cultures, providing an over-
simplified view of tumor biology.[105] To understand the mecha-
nisms underlying these complex tumor-stroma interactions, 
as well as their impact on tumor phenotypes, it has become 
clear that better in vitro multicellular models and better animal 
models are needed.[104] For this reason, in this section we pro-
vide an overview of the main metastatic cancer mouse models 
in use today, as well as the evolution of these models into new 
and improved forms of research such as tumor-on-a-chip, 
which implement 3D bioprinting technology. With all this, the 
advantages and disadvantages of metastasis study models will 
be observed, reflecting the need for the continuous implemen-
tation of new models for the investigation of this pathological 
process.
4.1. Experimental Models on Mice: A Limited Model
4.1.1. Spontaneous and Induced Metastasis Models
There is a wide variety of mouse metastasis models, including 
spontaneous metastasis models and induced metastasis 
models, including in turn allograft and xenograft models. 
Spontaneous metastasis models allow the study of the cells 
spread from a primary tumor to secondary sites in animals, 
that have received ectopic (out of the normal place) or ortho-
topic (within the normal place) injection of cancerous cells or 
tissue.[106] However, this model presents serious limitation. 
Tumor cell lines implanted subcutaneously in mice generally 
tend to grow rapidly and, therefore, do not mimic the doubling 
times of most human cancers, which are usually much slower. 
It is also unclear whether subcutaneously implanted ectopic 
tumors, which remain a standard methodology, will respond to 
therapy in the same way if cultured in an orthotopic organ.[107] 
On the other hand, experimental metastasis models are used 
to evaluate the ability of cancer cells to extravasate and grow 
in particular organs after intravascular injection (Figure  2), 
whether it is the lateral tail vein, intraportal and intracardiac, 
which in turn defines the site of colonization.[108] Nonetheless, 
this model does not reflect the initiation of the metastatic cas-
cade and is limited to the study of the biological processes that 
occur once the tumor cells are in the bloodstream. Despite this, 
these models have been fundamental in the current knowledge 
of the interactions that CTCs have with secondary organs and 
their colonization.[106]
The cellular origin of both models is therefore a very impor-
tant characteristic that must be taken into account. Allograft 
models are generated by transplanting cancer cells and mouse-
derived tumors into mice, that is, between equal species. The 
use of genetically identical single models, thus preventing 
graft-versus-host reactions, allows investigation of the immune 
system in cancer progression and identification of new thera-
peutic opportunities.[120] Unlike allograft models, xenografts 
involve human cells, which must be introduced into immu-
nocompromised or immunodeficient mice to prevent host 
rejection, being this the main advantage; however, the main 
drawback is the lack of a strong immune system in the host 
that, as it has been describe above, plays a fundamental role 
in the metastatic processes.[103] Hence, the use of xenograft 
mouse models in metastatic studies has been limited to highly 
metastatic tumors, such as MDA-MB-231 triple negative breast 
cancer cells, KM12 colon carcinoma cells and WM239A mela-
noma cells, which overcome the problem of limited metastatic 
potential.[58,121]
In addition, there are other drawbacks related with the use 
of mice models. For xenografts, the extraction of cancer cells 
involves their subsequent in vitro culture, which generally 
loses the characteristics of the original tumor, not reflecting 
the pheno typic and genetic heterogeneity of human cancers.[122] 
In an attempt to solve this problem, patient derived xenografts 
(PDX) have been developed. To avoid the selection pressures 
that occur in vitro, PDX are generated from resected tumors 
and implanted directly in immunocompromised mice by ortho-
topic or subcutaneous transplantation. While several studies 
have shown that PDX reflects human cancer diversity by reca-
pitulating the histology and metastatic characteristics of the 
original tumor,[123–125] other studies show that the grafting rate 
is low and that the site and frequency of PDX metastasis may 
vary from that seen in the patient. Furthermore, again the lack 
of an intact immune system represents an important limita-
tion, which is essential for tumor drift, and the presence of a 
mouse stromal makes PDX not an ideal model to study the role 
of the TME in human disease progression.[126,127]
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4.1.2. Genetically Engineered Mouse Models
Possible alternatives to xenografts models include genetically engi-
neered mouse models (GEMMs), which have been developed and 
used to study many aspects of tumor biology.[128] The generation of 
these models involves alterations in gene expression (overexpres-
sion or suppression) with particular emphasis on those genes that 
play a major role in the type of tumor involved (Figure 2).[129,130] 
Such models offer several advantages, most notably the genera-
tion of orthotopic tumors in immunocompetent hosts that often 
reflect their respective human tumor histotypes and contain a 
stromal and vasculature of the same species.[106] This is why this 
type of model has been particularly effective in studying early 
events in tumorigenesis. However, they have not been able to 
replace xenograft models as reliable clinical predictive tools for 
examining the efficacy of various types of metastatic treatments. 
This may, at least in part, be because such models generally show 
a low incidence of distant metastatic disease.[131]
However, once again these models have major disadvan-
tages: the microenvironment where the study tumor develops 
occurs in the mouse rather than in a human microenviron-
ment; sometimes the promoters and oncogenes used are not 
truly representative of human disease, and they may not be well 
defined to a specific lineage; penetration is generally low, while 
there is a long latency in terms of metastasis development; they 
have poor metastasis tropism and extensive mouse breeding 
programs are often required, which involves a great deal of 
time and resources.[106]
4.2. 3D Bioprinting: A New Step into the Future
The field of tissue engineering, including the use of 3D bio-
printing to generate complex tissues, has seen rapid advances 
in recent years toward the modeling of both normal tissues 
and disease states.[132–134] Thus, 3D bioprinting allows the 
generation of tissues that incorporate a variety of cell types in 
a complex and defined spatial architecture whose main motiva-
tion is to better mimic human physiology and functions at mul-
tiple scales, from the molecular level to the organ level across 
Figure 2. Evolution of metastasis research models. The study of metastasis encompasses a large number of models, starting with in vivo models 
in mice, which are still used. Subsequently, 3D bioprinting will play a fundamental role, from the most robust models through the construction of 
hydrogels that attempt to simulate the TME, to the most recent on-a-chip models, which are capable of recreating not only the TME but also the 
recreation of a vascular system that irrigates the tumor cells, thus allowing a better study of the metastatic process. Tumor-on-a-chip, Metastasis-on-
a-chip, Microfluidics, On-a-chip-models: Reproduced with permission.[17] Copyright 2019, MDPI. Tumor level functions on-a-chip, Multiorgan models: 
Reproduced with permission.[158] Copyright 2020, John Wiley and Sons.
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the cellular, multi-cellular, and tissue levels.[15] The resolution of 
3D bioprinting techniques is around 300 µm, which is subop-
timal if precise control of cell positioning is required.[135]
As an additive manufacturing technique, 3D bioprinting 
is based on the deposition of biomaterials, either by encapsu-
lating cells or by subsequently bioprinting cells on a micro-
metric scale to form subtle structures comparable to tissues. 
One of the most broadly used type of bioprinting is bioplotting, 
which is an extrusion-based technique consisting of a three-
axis mechanical platform that controls the movements of an 
extruder. The bioink is then deposited following a predefined 
numerical code that translates into coordinates for the three-
axis platform the shape desired by the designer. Due to advan-
tages such as deposition accuracy, cost-effectiveness, simplicity, 
and control of cell distribution, the development of 3D bio-
printing and its applications have been steadily increasing over 
the past few years. As a result of this development, the need has 
arisen to generate new bioinks that provide properties required 
for successful bioprinting, such as bioinks printability, fidelity, 
and cell viability.[14] In this sense, bioinks play a fundamental 
role, since they can become the TME when used for research 
in the fight against cancer. In this way, recent studies are aimed 
at generating bioinks from decellularized tumor matrix, recre-
ating this TME in a more faithful way. Piccoli et al. (2018), for 
example, developed a decellularized colorectal cancer matrix for 
the 3D in vitro study of this cancer. In this way, they describe an 
innovative approach to tissue engineering applied to colorectal 
cancer (CRC) from decellularized human biopsies to generate a 
bioactive 3D organotypic model. This in vitro 3D system reca-
pitulates the ultrastructural environment of the native tissue 
demonstrated by histology, immunohistochemistry, immuno-
fluorescence, and scanning electron microscopy analysis. Thus, 
they demonstrated the capacity of biofabrication of 3D acellular 
matrices preserving their biological properties. Given the bio-
logical activity that the scaffolds maintained after decellulariza-
tion, this approach is believed to be a powerful tool for future 
research and preclinical testing.[136]
Hydrogels with 3D hydrophilic polymer networks are one 
of the most promising and most widely used biomaterials in 
3D bioprinting (Figure  2) thanks to their high biocompatibility, 
exceptional permeability and appropriate rigidity, and are recog-
nized as preferable options for in vitro tissue and organ model 
engineering. In cell culture, hydration and porosity of hydrogels 
are indispensable parameters to provide a suitable environment 
for the proper functioning of cells.[137] Likewise, hydrogels also 
allow the exchange of nutrients, gases, and metabolic waste 
derived from the cell metabolism itself. In this way, there are 
different types of hydrogels (natural, synthetic, and hybrid) that 
have robustly allowed the study of the cellular microenviron-
ment.[15] Thus, for example, Luker et al. (2018) generated a hybrid 
hydrogel system composed of collagen and alginate to model the 
environments of tumors in breast cancer and other malignancies 
where all the material properties of the hydrogel were taken into 
account, including rigidity, microstructure and porosity, covering 
parameters present in normal organs and tumors. By embedding 
multicellular tumor spheroids, a 3D model of tumor invasion 
was constructed, demonstrating the effects of CXCL12-CXCR4 
signaling, a pathway involved in tumor progression and metas-
tasis, in a 3D hydrogel double tumor spheroid invasion model.[138]
As a result, and in combination with this 3D bioprinting, new 
models have emerged for the study of different pathologies, the 
on-a-chip models (Figure  2), as an effective methodology for 
mitigating the major disadvantages of animal models to com-
plete the understanding of different pathologies, including 
tumors and, therefore, metastasis.
4.3. Lab-On-Chip Technology Applied in Cancer
4.3.1. Tumor-On-A-Chip Technology
Organs-on-a-chip are microfluidic cell culture devices com-
posed of optically clear plastic, glass, or flexible polymers, 
such as PDMS, which contain perfused hollow microchannels 
populated by continuously perfused living cells that recapitu-
late in vivo the physiology and physiopathology at the organ 
level, recreating in vitro structures and functions of tissues and 
organs.[13] The objective is not to build a complete living organ, 
but to synthesize minimal functional units that recapitulate the 
functions at the level of tissues and organs. The simplest organ-
on-a-chip systems are composed of a single, perfused micro-
fluidic chamber containing a type of cultured cell that exhibits 
functions of a tissue type. In more complex designs, two or 
more microchannels are connected by porous membranes, 
lined on opposite sides by different cell types, thus recreating 
interfaces between different tissues, such as an endothelial 
barrier, while allowing analysis of specific organ responses, 
including recruitment of circulating immune cells, in reaction 
to drugs, toxins, or other environmental disturbances.[139] These 
devices can also be flexible and contain hollow side chambers 
through which cyclic suction can be applied to rhythmically 
stretch and relax the organotypic tissue interfaces, thereby 
mimicking the mechanical signals relevant to the organs, and 
replicating the air–liquid interfaces (ALI), fluid flow, and associ-
ated physiologically important shear stresses.[13]
As seen so far, the organ-on-a-chip has great potential 
for research into the basic mechanisms of organ physiology 
and disease. Therefore, these models are optimal for the 
study of biological phenomena that depend on tissue micro-
architecture and perfusion, as well as physiopathological 
processes.[139] Although the culture of a single cell type can 
mimic some characteristics of the tissue microenvironment, 
it is not usually sufficient to generate functionality similar to 
that of the organs. An organ is a hierarchical structure com-
posed of two or more different tissues, which in turn are 
formed by groups of different cell types. Therefore, to fully 
replicate this functionality, it is necessary to combine two or 
more different tissue types. With all this and thanks to the 
evolution of these models in recent years, it has been pos-
sible to mimic the TME for the study of this pathology in the 
named as tumor-on-a-chip. These devices allow the study of 
the specific steps of the cancer cascade, such as growth and 
expansion of the tumor, angiogenesis, progression of lesions 
from early stage to late stage involving EMT, invasion and 
metastasis of tumor cells.[13]
Tumor-on-chip models provide a unique biomimetic envi-
ronment to recapitulate all the events mentioned in metastatic 
screening and can be used to help us better understand the 
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behavior of new drugs in cancer. These models can easily 
recreate cell–cell or cell-ECM interactions, chemical/physical 
gradients, space-time or the (hydro)dynamic properties of the 
cellular microenvironment.[140] Also, these models solve the 
important limitation of in vitro models, such as the lack of a 
functional network of blood vessels to transport nutrients and 
gases, and to remove toxic products generated by the cells. 
Recent studies have provided evidence that these on-a-chip sys-
tems can provide a low-cost and physiologically relevant study 
model as an alternative to standard in vitro and in vivo models 
for clinical applications.[139,141–143] In this way, several research 
groups are developing better tumor-on-a-chip models.
Carvalho et  al. (2019) managed to develop a tumor-on-a-
chip model on a CRC chip for precision medicine, recreating a 
hydrogel with colon cancer cells covered with endothelial cells 
on a PDMS chip. Model validation was performed through 
integrated feasibility studies with in vivo imaging to confirm 
the dose-response effect of cells exposed to the carboxymethyl 
chitosan-grafted-terminal carboxyl group-poly(amidoamine) 
(CMCht/PAMAM) nanoparticle gradient. This platform also 
allows the analysis of gene expression, where a down-regula-
tion of all the genes studied related with invasion, proliferation 
and apoptosis was observed (MMP-1, Caspase-3, and Ki-67). The 
developed tumor-on-chip platform, which comprises a nucleus 
similar to that of a human CRC and the surrounding vascular-
ized microtissue, is a promising tool that presents numerous 
advantages over conventional models, whether for high-content 
image-based examinations or for analysis of gene expression to 
study responses to drug doses, as well as all the advantages pre-
sented by these models that will be discussed below.[144]
Another recent study by Lu et al. (2018) developed a 3D bio-
mimetic liver tumor-on-a-chip with the integration of essential 
components derived from the decellularized liver matrix (DLM) 
and GelMA, generating a dynamic 3D cell culture system based 
on microfluids. The biomimetic liver tumor-on-a-chip achieved 
greater cell viability and improved hepatocyte function under 
flow conditions. Thus, this improvement in tumor perfor-
mance based on DLM-GelMA can be attributed to the supply 
of biochemical factors, the preservation of scaffold proteins 
and the restoration of biophysical signals for better mimicry of 
the 3D liver EMT. In addition, this chip model exhibited linear 
dose-dependent pharmacological responses to paracetamol and 
sorafenib toxicity. Therefore, this study demonstrated that the 
liver tumor model faithfully mimicked the liver TME, making 
it possible to use this tool for a wide range of pathological and 
pharmacological studies.[145]
On the other hand, Aung et  al. (2020) described the devel-
opment of a multicellular perfusible tumor-on-a-chip platform 
involving different cell populations. Breast cancer cells, mono-
cytes and endothelial cells were spatially confined within a gel-
atin hydrogel in a controlled manner by 3D bioprinting. Using 
this platform, they examined cancer cell-myocyte interactions 
in the recruitment of T cells, which were allowed to infiltrate. 
In turn, a hypoxic environment was provided by the culture 
of tumor spheroids, demonstrating increased recruitment of 
T cells versus scattered cells with a less hypoxic environment. 
The addition of monocytes to the cancer cells improved T-cell 
recruitment. Thus, this study tested how effective was the 
development of a tumor-on-a-chip model involving heterotypic 
cells, as well as mimicking the recruitment of immune cells by 
the TME.[146]
4.3.2. One Step Further: Metastasis-On-A-Chip Technology
All these findings have allowed to go a step further in the study 
of metastasis. As mentioned above, the first events in the meta-
static cascade are tumor growth and invasion. Recently, some 
metastasis-on-a-chip (MoC) devices have been described for 
the analysis of these phenomena, which differ in the origin of 
the cancer cells, the architecture of the chip or the composition 
of the cellular microenvironment.[147,148] Some of these devices 
use SGC-7901 human gastric cancer cells[149] or NPC-BM1 naso-
pharyngeal carcinoma cancer cells,[150] with high metastatic 
capacity to obtain representative results. In the first of these, a 
microfluidic system was developed to detect highly metastatic 
sublines through the differential resolution of cell invasion. 
The system consisted of a PDMS glass device connected 
with a syringe pump and a petri dish. To facilitate the selec-
tion process, a long-term driving force based on a gradient of 
chemotactic factors was generated and the invasive cells were 
collected for selection through an open region on the chip. 
Using this system, a subline of SGC-7901/B2 of the human 
gastric cancer cell line SGC-7901 was established. In vitro tests 
showed that SGC-7901/B2 cells were superior to parental cells 
in terms of proliferation and invasion. In addition, an in vivo 
tumorigenicity trial showed that, compared to parental cells, 
the subline had a higher spontaneous metastatic and prolif-
erative capacity, which translated into a shorter survival time. 
This revealed the differences in protein expression, including 
E-cadherin and Smad3, between the subline and the parental 
cells. In conclusion, this microfluidic system proved to be a 
very effective tool for selecting highly metastatic sublines, and 
this SGC-7901/B2 cell subline could serve as a potential model 
for tumor metastasis research.[149]
In the second one, the NPC-BM1 nasopharyngeal carcinoma 
cancer model, a microfluidic device was generated for naso-
pharyngeal carcinoma that incorporated an impedance system 
for cell invasion quantitative measurement. The device con-
sisted of two tanks that were connected to a microchannel filled 
with a hydrogel. The malignant cells began to invade the micro-
channel and the impedance was simultaneously measured 
through electrodes located at the bottom of the microchannel. 
In this way, the process of cell invasion could be monitored in 
real time and in a non-invasive way. In addition, the cell inva-
sion rate was also calculated taking into account the correla-
tion between cell invasion and extracellular stimulation by IL-6 
cytokine, which showed that, indeed, the cell invasion rate was 
directly proportional to the IL-6 concentration, providing a reli-
able platform for future metastatic cell-based assays.[150]
Other research focused on the description of MoC system 
that would allow real-time monitoring of colon cancer 
through the fluorescence of cells migrating from 3D intestine 
hydrogel constructions (of hyaluronic acid) to another struc-
ture that mimic the liver, building a device with a circulatory 
fluid system that represents the TME, as well as a system to 
measure the effect of different drugs. The devices consisted 
of two chambers in which the intestine and liver were housed 
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independently, but which were in turn connected by the con-
tinuous flow of circulation. They showed how different tumor 
regions lost their membrane adhesion markers, and expressed 
mesenchymal and proliferative markers, suggesting a meta-
static phenotype.[10] These metastatic foci grew in size, even-
tually spreading from the intestine construction and entering 
the circulation, later reaching the liver construction, thus mim-
icking some of the migratory events observed during metas-
tasis. Finally, the system’s manipulative capabilities were also 
demonstrated, including chemical modulation and modifica-
tions of the mechanical properties of the hydrogel and the 
administration of chemotherapeutic agents, and the effects 
of these on the migration of invasive tumors were evaluated. 
Thus, these results describe the capacity of this MoC device, at 
an early stage of the tumor, to model several important charac-
teristics of metastasis, also demonstrating the potential to make 
significant advances in cancer research and the discovery of a 
drug effective against cancer.[10]
In a biochemical way, several studies of MoC have focused 
primarily on oxygen requirements, and some have looked at 
acidity and lactate levels. Such research has indicated that aero-
taxis (an active cell movement along gradients of oxygen)[151] is 
a relevant mechanism in cancer cell migration, and that acid 
and lactate gradients determine the direction of cancer cell 
invasion.[3] However, most experiments have focused on the 
study of metastatic invasion and intravasation. Liu et al. (2010) 
developed a microfluidic model that reconstitutes and is repre-
sentative of the metastatic process, containing the main com-
ponents of biological blood vessels, including vascular cavity, 
endothelium and perivascular matrix, which in turn contain 
chemokines. Using this model, the transendothelial invasion 
of the tumor aggregates can be observed and recorded in real 
time. In this study, the process of extravasation of the cystic 
adenoid carcinoma cell of the salivary gland (ACC) was ana-
lyzed. The ACC aggregates transmigrated through the endothe-
lium under CXCL12 chemokine stimulation, observing how 
the integrity of the endothelium was irreversibly damaged at 
the site of the transendothelial invasion. In turn, it was shown 
that the transendothelial invasion of ACC aggregates was inhib-
ited by AMD3100. Thus, this model allowed a detailed study of 
the process of transendothelial invasion of tumor aggregates, 
being therefore a useful tool for the analysis of the underlying 
mechanisms of metastasis and for testing new anti-metastatic 
agents.[148]
Ultimately, body-on-a-chip models represent the most devel-
oped systems for making a multi-organ model that mimics the 
interactions between multiple organs.[152] These recent advances 
aim to study organ–organ interactions as well as to investigate 
the ADME-tox methodology (absorption, distribution, metabo-
lism, and elimination) of different drugs that can be used to 
fight against several pathologies, including metastasis.[153]
Thus, Oleaga et  al. constructed a functional human model 
capable of evaluating multiorgan toxicity in a 4-organ system 
under continuous flow conditions in a defined environment 
without serum using a platform without a pump for 14 days. 
With this, they demonstrated the viability of the system, as well 
as the functional activity of the cardiac, muscular, neuronal, and 
hepatic modules. In addition, pharmacological relevance was 
evaluated in terms of their response at 7 days to 5 drugs with 
known side effects, doxorubicin, atorvastatin, acetaminophen, 
N-acetyl-m-aminophenol and valproic acid, after a 48 h drug 
treatment regimen. The results of all the pharmacological treat-
ments coincided with published toxicity results from human 
and animal data, making the next generation of in vitro systems 
increasingly realistic. This study has been a step toward an in 
vitro human on-chip assay for systemic toxicity detection.[118] 
In the same way, Skardal et  al. (2017) developed a set of bio-
engineered organoids and tissue constructions that were inte-
grated in a closed system of circulatory perfusion, allowing and 
facilitating the investigation of interorganic responses. In this 
system, a three-tissue organ-on-chip was accomplished, com-
posed of liver, heart, and lung, showing responses to drugs that 
depend on tissue interaction and illustrating the value of mul-
tiple tissue integration for in vitro study of both efficacy and 
side effects associated with candidate drugs. Investigating the 
potentially toxic effects of bleomycin on the lung organ model, 
adverse effects were observed in the cardiac organoid, which 
were not present when the cardiac model was treated with the 
same compound alone.[119]
Observing the advantages provided by the body-on-a-chip, its 
use in metastasis is a powerful study tool. Aleman & Skardal 
(2019) described a metastasis-on-a-chip device that hosts mul-
tiple 3D organoids created by a 3D photodesign technique 
using biomaterials from hydrogels derived from the ECM. 
Specifically, colorectal cancer cells, which resided in a single 
microfluidic chamber, were connected to multiple posterior 
chambers in which the rest of the organ constructions such as 
the liver, lung, and endothelium, were developed. In this way, 
the tumor cells grow at the primary site, under the flow of a 
recirculating fluid, to which they eventually enter into circula-
tion, and could be tracked by means of fluorescent imaging. 
It is important to note that they were able to demonstrate that 
in the current version of their system, the CRC HCT116 cells 
preferentially harbored the liver and lung constructs, the cor-
responding organs from which most CRC metastases arise in 
human patients, demonstrating once again the potential of 
these systems to mimic the metastatic process as it occurs in 
vivo.[116] In addition, Xu et  al. (2016) reported the design and 
construction of a multi-organ-on-a-chip that mimics the in vivo 
microenvironment of lung cancer metastasis. This multiorgan-
on-a-chip includes an ascending “lung” and three descending 
“distant organs”, with three layers of PDMS and two thin PDMS 
microporous membranes joined together to form three parallel 
microchannels. Bronchial epithelial, lung cancer, microvascular 
endothelial, mononuclear and fibroblast cells separated by the 
barrier in the ascending “lung” were cultured, while astrocytes, 
osteocytes, and hepatocytes were grown in distant chambers, 
thus mimicking the metastatic process of lung cancer cells 
in the brain, bone, and liver, respectively. After culture in this 
system, the lung cancer cells formed a “tumor mass”, showed 
an EMT (with altered expression of E-cadherin, N-cadherin, 
Snail1, and Snail2) and a high invasive capacity. A549 lung 
cancer cells that were cultured together with astrocytes overex-
pressed the CXCR4 protein, indicating the presence of astrocyte 
damage after metastasis of the cancer cells in the brain. On the 
other hand, the osteocyte overexpressed RANKL protein was 
also an indication of damage into bone due to metastasis of the 
cancer cells, as well as the overexpression of the AFP protein 
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in hepatocytes. Finally, in vivo imaging of cancer growth and 
metastasis in a mouse model validated the performance of 
metastasis in this multi-organ-on-a-chip system.[117]
4.3.3. The Great Potential of Tumor/Metastasis-On-A-Chip. Will 
They be Able to Replace the Current Models?
Conventional systems for metastasis analysis in mice and 3D 
cultures, including methods based on hydrogels, tissue engi-
neering, static cocultures, and bioreactors, have proved very 
useful for the study of certain behaviors at tissue and organ 
levels and for developing disease models. However, their 
major limitations have meant that new models have begun 
to emerge to fill these gaps and, in this regard, microfluidic 
culture devices have much to offer. A disadvantage of 3D mac-
roscale models without the addition of a chip is the difficulty 
of obtaining high-resolution images that allow to determine 
where in the tissue to look, in the same way, that it is diffi-
cult to visualize the processes in living organs. In addition, 
in organ-on-a-chip, cell types in one tissue can be positioned 
precisely and consistently concerning those in another, which 
has made it possible to integrate these systems with fluores-
cence confocal microscopy, microfluorimetry, transepithelial/
transendothelial electrical resistance (TEER) measurements, 
multiple electrode configurations, and many other analyt-
ical tests.[139] The screening of new drugs is also a strength 
of these models through high-throughput screening (HTS), 
allowing the generation of a large number of chips with sam-
ples of a tumor to test the effectiveness of different drugs on 
them.
To date, although a great advance has been made in the devel-
opment of tumor-on-a-chip models, there are still important 
limitations to be solved and which are being taken into account 
in future steps (Table  4). For example, tumor-on-a-chip plat-
form commonly uses cell lines, resulting in inconsistencies 
between the model and an original tumor. However, this limita-
tion is being solved with the use of patient biopsies that, on a 
small scale, would generate PDX-tumor-on-a-chip models that, 
without a doubt, would represent more powerful models than 
the current ones, avoiding the use of established cell lines.[154] 
The evolution of these models into more complex ones would 
finally solve the rest of the problems and, besides, this is being 
continuously observed: the change from tumor-on-a-chip to 
body-on-a-chip has been a matter of time and the implemen-
tation of increasingly complex vascular networks and target 
organs will be thanks to the development of new and more 
powerful instrumentation. Even, cell composition is not only 
the most important issue when designing a realistic model, but 
the general microenvironment and the ECM that makes it up 
are increasingly being taken into account. Thus, for example, 
although synthetic materials need to be used for the synthesis 
of the microenvironments, most of them have high biocompat-
ibility and they do not stop faithfully recreating the microenvi-
ronment with human cells. In addition, a new approach based 
in obtaining the ECM from decellularized human biopsies 
(both from healthy and tumor tissue) instead of using materials 
from another natural or synthetic source, is already being recre-
ated in chip models.[145,154]
Additionally, it is true that it is not possible to recreate 
tumors at real size (typically >109 cells); however, it is possible 
to reach a cellular range of 106 cells per mL,[155,156] which already 
Table 4. Advantages and disadvantages that present the current metastasis models depending on each step of it.
Metastasis steps 2D/3D cell culture Mouse models Tumor/metastasis-on-a-chip
Advantages Disadvantages Advantages Disadvantages Advantages Disadvantages
Local invasion and 
intravasation
Decellularized tumor 





Presence of synthetic 
materials (transwell cell 
invasion assay)
2D models cannot 





host if allograft and 
GEMM
Mouse TME
Applicable to limited 
number of cell lines
Immunocompromised 
host if xenograft




Easy study thanks to coupled 
techniques (microfluorimetry, 
TEER measurement…)




Circulation It is not possible to mimic the metastatic 
process since there is no circulatory system 
in this model
Circulation process 
occurs in a living 
organism
Presence of a complex 
natural vascular network








Difficulty in creating 





ment of metastasis in 
induced models








Presence of the complex 




Good extravasation due to 
permeable materials
Easy study thanks to coupled 
techniques (fluorescence 
confocal microscopy, multiple 
electrode configurations …)
Difficult to simulate the 
complex structure of the 
target organ
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allows for considerable cellular heterogeneity thanks also to the 
coupling with other techniques such as 3D bioprinting. This 
heterogeneity is the one, which really determines the behavior 
of the tumor and its replication on a small scale facilitates the 
study of them. Moreover, the inclusion of immune cells in 
the TME facilitates the correct mimicry since, as mentioned 
above, they play an essential role in the tumor development and 
metastatic process.
Despite these disadvantages, the fact that these models pre-
sent microfluidic systems providing perfusion (continuous, 
cyclic, or intermittent) offers a major advantage over static 
models, including spheroids and organoid cultures. This is 
especially important since it allows studies to focus on the 
neovascularization, invasion, and dissemination of cancer 
cells, as well as the possibility of maintaining cell viability and 
functionality for extended periods. The inclusion of endothe-
lial cells in the form of vasculature also offers greater clinical 
relevance for drug delivery studies, as well as for the devel-
opment of pharmacokinetic and pharmacodynamic (PK-PD) 
models,[157] where vascular tissue plays a key role. Thanks to 
this vascularization, the tumor model more accurately repre-
sents the TME, allowing in turn to observe invasion kinetics, 
tumor-blood vessel interaction, as well as drug interactions 
with endothelial barriers that represent a front to reach the 
tumor. The ability to establish controlled chemical gradients, 
achieve air liquid interface cell culture (ALI) to replicate the 
mechanical environments relevant to organs, and to model 
the fluids, shear stresses and hydrostatic pressures that exist 
in the ECM, represents an important additional advantage of 
these models.[13]
The real power of these systems lies in the ability to design 
synthetic culture method in which a large number of dif-
ferent parameters can be controlled: cell types and positions; 
molecular and specifically, oxygen gradients; precise 3D orien-
tation of tissue/tissue interfaces; levels and flow patterns and 
mechanical forcing regimes among others. All these variables 
can be varied independently while simultaneously obtaining 
high quality images in real time. This unprecedented level of 
control makes it possible to replicate different functional units 
of different organs that, sometimes and each on its chip, could 
be linked by vascular or interstitial channels to create synthetic 
models of whole organs.[139]
Although there are several works and research on chips, 
because of their potential, more areas of these tools need to 
be thoroughly investigated. With all this, future perspectives 
should focus on the use of decellularized matrix as bioinks for 
3D bioprinting. As discussed above, this decellularized matrix 
more accurately represent the TME of the tumor cells them-
selves, even with the same immune cells that, as discussed in 
this review too, play an important role in the development of 
the metastatic process. However, it would be important to take 
into account the variability among donors and therefore the 
need to establish a common protocol. Also, HTS would also be 
a good field to explore, which would be a further step toward 
precision medicine, allowing the verification of the effective-
ness of a large number of drugs for the same tumor, not only 
for the discovery of one, but for the personalized study for each 
patient.
5. Conclusions and Future Perspectives
Metastasis is a highly complex process that, despite being 
very inefficient, represents the major cause of cancer deaths. 
This is the reason why the need for metastatic study models 
has become very relevant in recent times. The progression of 
these models has been highly remarkable, going from studies 
in mice, which do not faithfully represent the human tumor 
behavior, to improved metastasis-on-a-chips-models that 
accurately and faithfully represent the TME, being a powerful 
device for the fight against cancer. These devices allow the con-
trol of a large number of parameters that improve the study of 
metastasis, as well as the representation of functional units of 
different organs to study cell migration, being at the same time 
low-cost models. However, many aspects of metastasis are not 
well known at present, so the evolution of these models must 
remain constant to finally understand all the steps that come 
into play in the metastatic process, as well as to obtain powerful 
tools for the screening of future drugs and toxicological studies.
Currently, these models are not applied in clinical practice 
and, observing all the advantages and opportunities they pre-
sent, it is a considerable challenge to implement them in daily 
clinical practice. Despite the disadvantages or limitations they 
may have (i.e., the use of established cell lines or the impos-
sibility of generating full-size tumors), it has already been 
observed how they are overcome by their potential and how 
they could be a clear evolution in the way of treating patients, 
with a clear personalized approach. Thus, the tumor-on-a-chip 
and metastasis-on-a-chip models would be a great and modern 
tool for the development of personalized treatments that, for-
tunately, will manage to realize a previously therapeutic HTS 
from a small patient biopsy that allow to implement more 
precise treatment regimens that will result in the reduction of 
deaths due to metastasis.
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